Gene profiling for defining targets for new therapeutics in autoimmune diseases by Rogge, Lars
47
EAE = experimental autoimmune encephalomyelitis; Fc = crystallizabe fragment; IL = interleukin; MS = multiple sclerosis; NF = nuclear factor; 
OPN = osteopontin; Tc = CD8+ T cells; Th = T helper cell.
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Introduction
Genomic-scale gene expression profiling has an increas-
ing impact on immunology and, in particular, on the char-
acterization of immunological diseases. This profiling
technology can reveal the physiology of cells and tissues
on an unprecedented scale by quantitating, in parallel, the
mRNA levels of tens of thousands of genes [1].
Global gene expression studies rely mainly on two tech-
nologies: spotted cDNA microarrays, and high-density
oligonucleotide microarrays [2,3] (for reviews of the two
technologies, see [4,5]). Microarray experiments generate
an amount of data that cannot be handled by simple
sorting in spreadsheets or plotting on graphs. Microarray
data analysis therefore requires dedicated algorithms and
tools [6]. Sophisticated computational tools are available,
but it is important to note that a basic understanding of
these tools is required for meaningful data analysis.
Several recent reports demonstrated the power of the
combination of gene expression profiling and dedicated
computational analysis tools for improved diagnosis and
prognosis of cancer.
Alizadeh  et al. used a specially designed ‘lymphochip’ to
characterize gene expression patterns of diffuse large B-cell
lymphoma, the most common subtype of non-Hodgkin’s
lymphoma [7]. A hierarchical clustering algorithm was used
to group genes on the basis of similarity in the pattern with
which their expression varied over all samples [8]. This strat-
egy allowed the authors to separate diffuse large B-cell lym-
phoma into two previously not recognized subtypes, which
had marked differences in patient survival [7]. A more recent
study demonstrated that molecular profiling can also have a
significant impact on the prediction of the clinical outcome
of cancer. van’t Veer et al. showed that gene expression
analysis of breast cancer tissue can predict patients that will
develop metastases with higher accuracy than currently
used clinical parameters [9].
In the following, I will review several studies that attempt to
further the understanding of autoimmune diseases using
molecular profiling. I will focus on the gene expression
analysis of T lymphocytes, the key players in several
inflammatory diseases, and on the microarray analysis of
brain tissue from patients with multiple sclerosis (MS).
The identification of novel targets for improved diagnosis and pharmaceutical intervention is of critical
importance for better treatment of autoimmune diseases in the future. The possibility to measure levels
of gene expression for tens of thousands of genes simultaneously and in a quantitative fashion will
greatly enhance our knowledge of genes and pathways involved in disease pathogenesis. Initial studies
have focused on the gene expression profiling of homogeneous cell populations. Genomic-scale gene
expression profiling has also more recently been applied to tissue samples from patients with
immunopathologies. The scope of the present review is to discuss recent progress in this field with
respect to the identification of novel target molecules.
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Transcript imaging of human and mouse
T helper cell subsets
T helper lymphocytes are essential to orchestrate appro-
priate immune responses to pathogens. To achieve effec-
tive immunity, T helper cells differentiate into at least two
specialized subsets that direct type 1 and type 2 immune
responses [10,11]. Cell-mediated (type 1) immunity is
necessary for protection against most intracellular
pathogens and, when excessive, can mediate organ-
specific autoimmune destruction [12]. This indicates that
the development of Th1 cells must be tightly controlled. To
learn more about the functional properties of human Th1
and Th2 cells and to identify molecules that could be of
interest for pharmacological intervention in chronic inflam-
matory diseases, we decided to analyze gene expression
profiles of human Th1 and Th2 cells. Polyclonal human
Th1 and Th2 cells were generated in vitro from cord blood
leukocytes [13]. To monitor changes of gene expression
occurring early in the differentiation process, Th1 and Th2
cells were purified 3 days after stimulation. In this initial
study, we used high-density oligonucleotide arrays with
the capacity to display transcript levels of 6000 human
genes [14]. After analyzing gene expression data from Th1
and Th2 cells derived from two independent donors, we
realized that it was very difficult to discriminate between
subset-specific and donor-specific changes in gene
expression. We therefore decided to analyze gene expres-
sion in Th1 and Th2 cells generated from three additional
donors and to analyze the dataset using a statistical algo-
rithm (paired t test).
The importance of replicate microarray experiments has
recently been emphasized in a study addressing the
natural differences in mouse gene expression [15]. The
authors used a 5406-clone spotted cDNA microarray to
quantitate transcript levels in the kidney, the liver, and
the testis from each of six normal male C57BL6 mice.
Analysis of variance was used to compare the variance
across the six mice with the variance among four repli-
cate experiments performed for each tissue. The striking
finding was that statistically significant variable gene
expression was detected for 3.3%, 1.9%, and 0.8% of
the genes in the kidney, the testis and the liver, respec-
tively [15]. Importantly, many of the transcripts that were
found most variable were immune-modulated genes,
stress-induced genes, and hormonally regulated genes.
This finding may raise some doubt about the validity of
the data reported in several published microarray studies
performed with only one or two replicate experiments.
Pritchard et al. further point out that genetically diverse
populations such as humans are very likely to show an
even greater variability in gene expression than inbred
mice [15]. This suggests that a meaningful interpretation
of global gene expression in humans will require many
replicate experiments and/or an extensive characteriza-
tion of normal variability.
To exert their functions, type 1 and type 2 T lymphocytes
have to home into different sites. We reported an
increased expression of mRNA for fucosyltransferase VII,
which codes for an enzyme that mediates the fucosylation
of selectin ligands on the surface of T cells [14]. This fuco-
sylation is required for the first step of lymphocyte adhesion
to endothelial cells (‘rolling’). Recent in vivo observations
have validated the biological relevance of this finding.
Fucosyltransferase VII was in fact found to be upregulated
on T cells infiltrating the inflamed joints of patients affected
by either rheumatoid arthritis [14] or juvenile idiopathic
arthritis [16]. In both diseases, the T cells infiltrating the
synovium have a clear Th1 phenotype.
In a subsequent study, Chtanova et al. used high-density
oligonucleotide microarrays to analyze gene expression in
murine CD4+ Th1 and Th2 cells, as well as CD8+ type 1
and type 2 T cells (Tc1 and Tc2) [17]. In contrast to our
study where Th1-overexpressed genes predominated
[14], Chtanova et al. identified more type 2-biased genes
[17]. It is important to note that different protocols were
used to generate polarized T-cell subsets in the two
studies. Chtanova et al. stimulated purified naïve mouse
CD4+ and CD8+ T cells with anti-CD3/CD28 antibodies,
IL-2 and IL-6 plus the polarizing cytokine cocktail. Cells
were cultured for 7 days and then restimulated for
24 hours with anti-CD3 before extracting RNA. A previous
report has demonstrated that IL-6 is able to polarize naïve
CD4+ T cells into Th2 cells by inducing the initial produc-
tion of IL-4 in CD4+ T cells [18]. In addition, it has been
shown that IL-6 inhibits Th1 differentiation in an IL-4-inde-
pendent manner through the induction of SOCS1 [19].
The addition of IL-6 to the cultures could therefore be a
possible explanation for the Th2-bias observed in that
study [17]. As expected, CD4+ and CD8+ T-cell subsets
expressed their signature cytokines. In addition, Chtanova
et al. found two members of the tumor necrosis factor
receptor-associated factor family to be differentially
expressed in type 1 and type 2 cells. TRAF4 was
expressed at a higher level in type 1 cells while TRAF5
was preferentially expressed in type 2 cells. Members of
this family serve as adapter proteins that mediate cytokine
signaling; in particular, they seem to play a role in tumor
necrosis factor and Toll/IL-1 signaling, resulting in activa-
tion of transcription factors NF-kB and activator protein 1.
Much work clearly remains to be done to address the bio-
logical relevance of these findings.
Together, these results demonstrate the impact of large-
scale gene expression profiling on the analysis of distinct
T lymphocyte populations. The analyses of the expression
of 6000 genes in human Th1 and Th2 cells and of 11,000
genes in mouse Th1, Tc1, Th2 and Tc2 cells were first
attempts to understand the molecular mechanisms under-
lying the functional diversity of distinct T-cell subsets. The
finding that genes regulating key steps in the process of49
leukocyte extravasation into inflamed tissues are coregu-
lated in human T-cell subsets sheds light on the impor-
tance of the correct positioning of T cells within tissues to
eliminate pathogens. Moreover, autoimmune diseases are
associated with the presence of specialized subsets of
T helper cells at the site of inflammation. Knowledge of the
genetic program that controls the differentiation and func-
tional properties of Th1 cells versus Th2 cells may there-
fore increase the understanding of inflammatory diseases.
Gene expression analysis of MS lesions
MS is characterized by the infiltration of T cells and other
immune cells into the white matter of the central nervous
system. The resulting inflammation and subsequent
destruction of myelin cause progressive paralysis and a
variety of other neurological symptoms [20,21]. The diver-
sity of symptoms and of the disease course complicates
diagnosis and the understanding of the pathogenesis of
MS. Much of our current knowledge of MS stems from the
analysis of a mouse model of MS. Experimental autoim-
mune encephalomyelitis (EAE) is a T-cell-mediated autoim-
mune disease with striking clinical and histopathological
similarities to MS. Unfortunately, EAE has failed several
times in predicting the efficacy of new therapeutics [22].
In an attempt to identify genes that contribute to lesion
pathology, several groups have analyzed gene expression
in brain tissue obtained postmortem from MS patients and
compared it with tissue samples from individuals without
MS [23–26]. Given the heterogeneity of the disease, and
also the small numbers of patients that have so far been
analyzed, it is not surprising that the results are only par-
tially overlapping. Yet the results are encouraging since
they provide the first hints of novel targets for anti-inflam-
matory treatment of MS. Whitney et al. screened cDNA
microarrays with 33P-dCTP-labeled cDNAs generated
from MS lesions and normal white matter [24]. Among
other genes, they identified arachidonate 5-lipoxygenase,
a key enzyme in the biosynthetic pathway of leukotrienes,
to be overexpressed in MS. Immunohistochemistry con-
firmed this finding, and 5-lipoxygenase staining was mainly
detected in cells resembling macrophages and monocytes.
The authors point out that 5-lipoxygenase upregulation is
not unique to MS, but is also found in other central nervous
system diseases where macrophages and monocytes are
activated, such as cerebral infarction and meningitis.
Using large-scale sequence analysis of cDNA libraries
generated from brain tissue of MS patients, Chabas et al.
identified a number of cDNAs that were over-represented
in the MS libraries when compared with libraries con-
structed from control brain tissue [25]. Among these was
osteopontin (OPN), a cytokine with pleiotropic functions
including roles in inflammation and immunity to infectious
diseases. Previous work had attributed a key role to OPN
in the regulation of Th1-mediated immune responses by its
effects on IL-12 and IL-10 production [27]. Immunohisto-
chemistry revealed increased expression of OPN adjacent
to lesions observed in the brain tissue of MS patients, as
well as in rodents that develop an experimental form of the
disease [25]. The induction and severity of EAE and the
expression of inflammatory cytokines by T cells were
greatly reduced in mice lacking the OPN gene [25].
Increased expression of OPN has also been found in
inflamed joints of rheumatoid arthritis patients [28]. These
observations make OPN an attractive target for anti-inflam-
matory therapy of MS, and possibly rheumatoid arthritis.
Lock  et al. more recently compared gene expression in
two distinct types of neuronal lesions: acute active lesions
with inflammation, and chronic silent lesions without
inflammation [26]. Granulocyte colony-stimulating factor
was found highly expressed in acute lesions, but not in
silent lesions. In contrast, transcripts encoding the IgG Fc
receptor I were found overexpressed in silent lesions. The
importance of these two molecules in the pathogenesis of
MS was assessed in the EAE model. Treatment with gran-
ulocyte colony-stimulating factor before the onset of EAE
decreased the severity of the acute phase but had no
effect on the late stages of the disease. The role of Fc
receptors in EAE was studied by comparing the severity of
disease in Fc receptor-deficient and wild-type mice. Acute
disease was less severe and chronic disease was absent
in Fc receptor knockout mice [26]. This study by Lock
et al. is the first example demonstrating the value of
microarray technology for the analysis of distinct disease
states of MS. Together with additional studies that are
sure to follow, it may pave the way for an improved diagno-
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